Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Cell Physiol Biochem ; 48(3): 1075-1087, 2018.
Article in English | MEDLINE | ID: mdl-30041179

ABSTRACT

BACKGROUND/AIMS: MIAT is a long noncoding RNA (lncRNA) involved in cell proliferation and the development of tumor. However, the exact effects and molecular mechanisms of MIAT in clear cell renal cell carcinoma (ccRCC) progression are still unknown. METHODS: We screened the lncRNAs' profile of ccRCC in The Cancer Genome Atlas database, and then examined the expression levels of lncRNA MIAT in 45 paired ccRCC tissue specimens and in cell lines by q-RT-PCR. MTS, colony formation, EdU, and Transwell assays were performed to examine the effect of MIAT on proliferation and metastasis of ccRCC. Western blot and luciferase assays were performed to determine whether MIAT can regulate Loxl2 expression by competitively binding miR-29c in ccRCC. RESULTS: MIAT was up-regulated in ccRCC tissues and cell lines. High MIAT expression correlated with worse clinicopathological features and shorter survival rate. Functional assays showed that knockdown of MIAT inhibited renal cancer cell proliferation and metastasis in vitro and in vivo. Luciferase and western blot assays further confirmed that miR-29c binds with MIAT. Additionally, the correlation of miR-29c with MIAT and Loxl2 was further verified in patients' samples. CONCLUSION: Our data indicated that MIAT might be an oncogenic lncRNA that promoted proliferation and metastasis of ccRCC, and could be a potential therapeutic target in human ccRCC.


Subject(s)
Amino Acid Oxidoreductases/metabolism , Carcinoma, Renal Cell/pathology , Kidney Neoplasms/pathology , MicroRNAs/metabolism , RNA, Long Noncoding/metabolism , Amino Acid Oxidoreductases/chemistry , Amino Acid Oxidoreductases/genetics , Animals , Antagomirs/metabolism , Binding, Competitive , Carcinoma, Renal Cell/genetics , Cell Line, Tumor , Cell Proliferation , Female , Humans , Kidney Neoplasms/genetics , Male , Mice , Mice, Nude , MicroRNAs/genetics , Middle Aged , Neoplasm Metastasis , RNA Interference , RNA, Long Noncoding/antagonists & inhibitors , RNA, Long Noncoding/genetics , RNA, Small Interfering/metabolism , Up-Regulation
2.
Exp Cell Res ; 358(2): 269-278, 2017 09 15.
Article in English | MEDLINE | ID: mdl-28684115

ABSTRACT

Caveolin-1 (CAV1) has been identified to be up-regulated in many cancers, including clear cell renal cell carcinoma (ccRCC). However, its potential function is still unclear in ccRCC. In this study, we demonstrated that CAV1 was frequently overexpressed in renal cell carcinoma tissues and cells, and was significantly associated with various clinicopathological parameters. In addition, high CAV1 expression was associated with poor disease-free survival (DFS) rate and could serve as a useful diagnostic indicator in ccRCC patients with different clinicopathological stages. Functional experiments demonstrated that CAV1 knockdown inhibited cell migration and invasion, whereas overexpression of CAV1 promoted cell migration and invasion in ccRCC. Moreover, CAV1 expression was up-regulated in sunitinib-resistant renal cancer cell lines, and its overexpression promoted sunitinib resistance. In general, our results confirm that CAV1 plays an important role in the metastasis of kidney cancer and induces sunitinib resistance, so CAV1 function suppression may become a promising clinical treatment strategy during renal cell carcinoma metastasis and sunitinib resistance.


Subject(s)
Carcinoma, Renal Cell/metabolism , Caveolin 1/metabolism , Cell Movement/physiology , Drug Resistance, Neoplasm , Gene Expression Regulation, Neoplastic/genetics , Indoles/pharmacology , Kidney Neoplasms/metabolism , Pyrroles/pharmacology , Adult , Aged , Aged, 80 and over , Caveolin 1/genetics , Cell Proliferation/genetics , Cell Proliferation/physiology , Female , Gene Knockdown Techniques/methods , Humans , Kidney Neoplasms/pathology , Male , Middle Aged , Neoplasm Invasiveness , Prognosis , Sunitinib , Young Adult
3.
Cell Physiol Biochem ; 43(6): 2420-2433, 2017.
Article in English | MEDLINE | ID: mdl-29073615

ABSTRACT

BACKGROUND/AIMS: We previously performed microRNA (miRNA) microarray to identify effective indicators of clear cell renal cell carcinoma (ccRCC) tissue samples and preoperative/postoperative plasma in which we identified miR-144-3p as an oncomiRNA. However, the molecular mechanism of miR-144-3p remains unclear. This study aims to explore the roles of miR-144-3p in the invasion, migration and Sunitinib-resistance in ccRCC and to elucidate the underlying mechanisms. METHODS: Gain and loss of function approaches were used to investigate the cell proliferation, cycle distribution, clonogenicity, migration, invasion, chemosensitivity of miR-144-3p in vitro. The xenograft model was used to assess the effects of miR-144-3p overexpression on tumorigenesis. Bioinformatics analysis and dual-luciferase reporter assay were used to indentify AT-rich interactive domain 1A (ARID1A) as a direct target gene of miR-144-3p. Quantitative RT-PCR, Western blotting, and immunohistochemical (IHC) staining were used to explore ARID1A expression level of the mRNA and protein. RESULTS: We found that miR-144-3p overexpression enhanced cell proliferation, clonogenicity, migration, invasion, and chemoresistance in ccRCC cells. Notably, the oncotumor activities of miR-144-3p were mediated by repressing the expression of ARID1A. The downregulation of ARIDIA could promote the function of miR-144-3p in cell proliferation, metastasis and chemoresistance. Consistently, ARID1A mRNA and protein levels were decreased in ccRCC and in nude mice, and they negatively correlated with miR-144-3p. CONCLUSION: Higher miR-144-3p may enhance malignancy and resistance to Sunitinib in ccRCC by targeting ARID1A, the observations may uncover novel strategies of ccRCC treatment.


Subject(s)
Carcinoma, Renal Cell/pathology , Drug Resistance, Neoplasm , Kidney Neoplasms/pathology , MicroRNAs/metabolism , Nuclear Proteins/metabolism , Transcription Factors/metabolism , 3' Untranslated Regions , Animals , Antagomirs/metabolism , Base Sequence , Carcinogenesis , Carcinoma, Renal Cell/drug therapy , Carcinoma, Renal Cell/metabolism , Cell Cycle Checkpoints , Cell Line, Tumor , Cell Movement , Cell Proliferation , DNA-Binding Proteins , Down-Regulation , Humans , Indoles/therapeutic use , Kidney Neoplasms/drug therapy , Kidney Neoplasms/metabolism , Male , Mice , Mice, Nude , MicroRNAs/antagonists & inhibitors , MicroRNAs/genetics , Mutagenesis , Nuclear Proteins/antagonists & inhibitors , Nuclear Proteins/genetics , Pyrroles/therapeutic use , RNA Interference , RNA, Small Interfering/metabolism , Sequence Alignment , Sunitinib , Transcription Factors/antagonists & inhibitors , Transcription Factors/genetics , Transplantation, Heterologous , Up-Regulation
9.
Arch Dermatol Res ; 315(6): 1655-1664, 2023 Aug.
Article in English | MEDLINE | ID: mdl-36780005

ABSTRACT

Basal cell carcinoma (BCC) is rare in young individuals and reported to possess different pathogenetic, clinical and histological features from late-onset BCC. However, the dermoscopic variability of BCC according to age of onset has not been investigated. Anatomic location was revealed to be associated with dermoscopic variation of BCC in Western population, but whether it applies to Asian population remains unknown. We evaluated the clinical and dermoscopic features of 448 BCCs and compared each feature by age of onset (age < 50/ > 50 years) and anatomic location. Early-onset BCCs occurred more frequently on non-sun-exposed sites (OR 3.28, P = 0.001) and were less pigmented than late-onset BCCs (P = 0.003). Blue-gray globules (OR 1.74, P = 0.037) and no vessels (OR 2.04, P = 0.021) were independently associated with early-onset BCCs, whereas arborizing telangiectasia (OR 0.30, P < 0.001), large blue-gray ovoid nests (OR 0.38, P < 0.001) and ulceration (OR 0.33, P < 0.001) were less common in early-onset BCCs. Scalp BCCs were significantly more pigmented than BCCs located elsewhere (P = 0.022). Superficial subtype (OR 5.90, P < 0.001), spoke-wheel areas (OR 4.78, P = 0.034), superficial erosions (OR 4.69, P = 0.003) and polymorph vessels (OR 6.86, P = 0.001) were independently associated with trunk BCCs, whereas nodular subtype (OR 5.48, P < 0.001) and arborizing telangiectasias (OR 3.64, P < 0.001) with BCCs on face and neck. Our findings suggest that age of onset and anatomic location are independent factors affecting the dermoscopic appearance of BCC.


Subject(s)
Carcinoma, Basal Cell , Skin Neoplasms , Humans , Middle Aged , Skin Neoplasms/diagnosis , Skin Neoplasms/epidemiology , Skin Neoplasms/pathology , Retrospective Studies , Age of Onset , Dermoscopy , Carcinoma, Basal Cell/epidemiology , Carcinoma, Basal Cell/pathology
10.
J Dermatol ; 49(6): 661-665, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35384058

ABSTRACT

Pulsed-dye laser (PDL), as an effective and frequently-used treatment modality for infantile hemangiomas (IH), could render patients at risk of developing long-term alopecia. Data on alopecia caused by PDL treatment remain scant and the contributing factors are not clear. Our objective was to identify the risk factors associated with long-term alopecia resulting from PDL treatment for scalp IH. We conducted a retrospective study incorporating patients with IH diagnosis and PDL intervention via thoroughly reviewing the clinical database of the dermatology department. Scalp IH patients were further screened and their medical records were collected. Long-term alopecia was defined as no signs of terminal hair regrowth for at least 2 years in this study. Of the 1293 IH patients, 47 (14 boys and 33 girls) with a mean age of 4.5 months (standard deviation, 3.2) were diagnosed as scalp IH and had subsequently undergone PDL treatments. Hair growth in the treatment area of 18 patients (38.3%) nearly returned to normal, 22 patients (46.8%) had varying degrees of hair loss, and seven patients (14.9%) had no hair regrowth (long-term alopecia). Compared with the older patients receiving treatment, IH patients younger than 3 months who started PDL treatment had a higher risk of developing long-term alopecia (odds ratio, 30.833; 95% confidence interval, 4.079-232.025; p = 0.01). The total number of PDL sessions, post-treatment blisters, and location of IH were not shown to be significantly associated with the development of long-term alopecia. Collectively, our study provides an important insight into curating treatments for IH in infants younger than 3 months. PDL treatments for scalp IH may perhaps be avoided or delayed to prevent the development of treatment-associated long-term alopecia.


Subject(s)
Hemangioma , Lasers, Dye , Alopecia/etiology , Female , Hemangioma/drug therapy , Humans , Infant , Lasers, Dye/adverse effects , Male , Retrospective Studies , Risk Factors , Scalp , Treatment Outcome
11.
Biochim Biophys Acta Mol Cell Biol Lipids ; 1864(8): 1091-1102, 2019 08.
Article in English | MEDLINE | ID: mdl-31002945

ABSTRACT

Cancer-associated cachexia (CAC) constitutes a metabolic dysfunction characterized by systemic inflammation and body weight loss. Muscle atrophy and adipose tissue lipolysis might explain weight loss in CAC. Specific functions of numerous hormones and cytokines derived from tumours can provoke cachexia. Extracellular vesicles (EVs) can be involved in intercellular communication. However, whether EVs participate in this process has not been investigated thoroughly. Using Lewis lung carcinoma (LLC) cell cultures, we tested whether LLC-derived EVs induced C2C12 myotube atrophy and 3T3-L1 adipocyte lipolysis. EVs derived from LLC cells and serum from patients with lung cancer, non-lung cancer controls, tumour-bearing mice, and non-tumour-bearing control mice were isolated and characterized biochemically and biophysically. LLC cell-derived EVs induced dose-dependent effects of atrophy in C2C12 myotubes and lipolysis in 3T3-L1 adipocytes. Mechanistically, EVs directly fused with target C2C12 myotubes and 3T3-L1 adipocytes, and transferred interleukin-6 (IL-6) activates the STAT3 signalling pathway in C2C12 myotubes and 3T3-L1 adipocytes. Neutralization of extracellular IL-6 prevented the atrophy and lipolysis effects of EVs. Inhibiting the STAT3 signalling pathway also prevented the atrophy and lipolysis effects of EVs. PKH67-labelled (PKH 67 is a lipid dye that can be used to label extracellular vesicles) LLC-EVs were readily internalized into myotubes and adipocytes. Our data showed that LLC cell-derived EVs induced myotube atrophy and adipocyte lipolysis via the extracellular IL-6-mediated STAT3 pathway in target cells. These findings represent a potentially novel basis for further research in this field towards identifying targets and developing strategies for maintaining weight in CAC.


Subject(s)
Adipocytes/metabolism , Extracellular Vesicles/physiology , Interleukin-6/pharmacology , Lung Neoplasms/pathology , Muscle Fibers, Skeletal/pathology , STAT3 Transcription Factor/metabolism , 3T3-L1 Cells , Animals , Atrophy/chemically induced , Cachexia/etiology , Carcinoma, Lewis Lung/pathology , Extracellular Vesicles/metabolism , Humans , Lipolysis/drug effects , Mice , Muscle Fibers, Skeletal/metabolism , Tumor Cells, Cultured
13.
J Exp Clin Cancer Res ; 36(1): 42, 2017 03 10.
Article in English | MEDLINE | ID: mdl-28283039

ABSTRACT

BACKGROUND: Growing evidence suggests that hepatitis C virus (HCV) contributes to hepatocellular carcinoma (HCC) by directly modulating oncogenic signaling pathways. Protein phosphatase magnesium-dependent 1A (PPM1A) has recently emerged as an important tumor suppressor as it can block a range of tumor-centric signaling pathways through protein dephosphorylation. However, the role and regulatory mechanisms of PPM1A in HCV-infected cells have not been reported. METHODS: Total, cytoplasmic, and nuclear PPM1A protein after HCV infection or overexpression of HCV nonstructural protein 3 (NS3) were detected by western blotting. The expression of PPM1A in normal liver and HCV-related HCC tissues was quantified by immunohistochemistry. The effects of HCV infection and NS3 expression on the PPM1A protein level were systematically analyzed, and the ubiquitination level of PPM1A was determined by precipitation with anti-PPM1A and immunoblotting with either anti-ubiquitin or anti-PPM1A antibody. Finally, the roles of NS3 and PPM1A in hepatoma cell migration and invasion were assessed by wound healing and transwell assays, respectively. RESULTS: HCV infection and replication decreased PPM1A abundance, mediated by NS3, in hepatoma cells. Compared to normal liver tissues, the expression of PPM1A was significantly decreased in the HCC tumor tissues and adjacent non-tumor tissues. NS3 directly interacted with PPM1A to promote PPM1A ubiquitination and degradation, which was dependent on its protease domain. Blockade of PPM1A through small interfering RNA significantly promoted HCC cell migration, invasion, and epithelial mesenchymal transition (EMT), which were further intensified by TGF-ß1 stimulation, in vitro. Furthermore, restoration of PPM1A abrogated the NS3-mediated promotion of HCC migration and invasion to a great extent, which was dependent on its protein phosphatase function. CONCLUSIONS: Our findings demonstrate that the HCV protein NS3 can downregulate PPM1A by promoting its ubiquitination and proteasomal degradation, which might contribute to the migration and invasion of hepatoma cells and may represent a new strategy of HCV in carcinogenesis.


Subject(s)
Carcinoma, Hepatocellular/virology , Hepacivirus/physiology , Liver Neoplasms/virology , Protein Phosphatase 2C/metabolism , Viral Nonstructural Proteins/metabolism , Carcinoma, Hepatocellular/metabolism , Cell Line, Tumor , Cell Movement , Cell Nucleus/metabolism , Cytoplasm/metabolism , HEK293 Cells , Hepacivirus/metabolism , Humans , Liver Neoplasms/metabolism , Neoplasm Invasiveness , Proteolysis , Ubiquitination
SELECTION OF CITATIONS
SEARCH DETAIL